Related Experiment Video
Updated: May 19, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
[Paediatric meningococcal meningitis in France: ACTIV/GPIP network results]
1GPIP-Groupe de Pathologie Infectieuse Pédiatrique de la SFP-Société Française de Pédiatrie, France. activ@wanadoo.fr
Background:
The GPIP/ACTIV (Groupe de Pathologie Infectieuse Pédiatrique and Association Clinique et Thérapeutique Infantile du Val de Marne) set up an active surveillance network to analyze the epidemiological, clinical and biological features of meningococcal meningitis.
Methods:
French pediatric wards working with 166 microbiology laboratories enrolled all children (0-18 years old) with bacterial meningitis. Risk factors, signs and symptoms, vaccination status, cerebrospinal fluid analysis, treatments and case fatality rate were recorded.
Results:
Since 2001, 1661 meningococcal meningitis were reported among 3769 (44.1%) bacterial meningitis. Mean age was 4.4- year- old (± 4.8, median 2.5) and 2/3 cases occurred in children under 5- year- old (68.8%). Serogroup B (61.3%) is preponderant following by serogroup C (27.0%). 27.5% of children had received an antibiotic treatment 24 hours before lumbar puncture. A shock is reported in 31.0% of cases. No cases of meningococcal meningitis C has been reported in children vaccinated with a conjugate vaccine. Two children vaccinated with MenBvac(®) vaccine had a meningitis B14:P1.7,16. Global case fatality rate was 6.5% but was higher (9.2%) for serogroup C than for serogroup B (5.9%) (p=0.02).
Conclusion:
This is among the largest series of microbiologically documented meningococcal meningitis to date (1661 cases). In France, meningococcal is responsible for approximately 50 % of meningitis. Effective meningococcal serogroup B vaccine and serogroup C vaccination recommendation could control the burden of meningococcal meningitis.
Insights
Meningococcal meningitis remains a significant threat, particularly in children under five. Vaccination against serogroups B and C is crucial for controlling this disease.
Area of Science:
- Pediatric Infectious Diseases
- Epidemiology
- Microbiology
Background:
- An active surveillance network was established to analyze meningococcal meningitis.
- The network focused on epidemiological, clinical, and biological features of the disease.
Purpose of the Study:
- To analyze the epidemiological, clinical, and biological features of meningococcal meningitis in children.
- To assess the impact of vaccination on meningococcal meningitis cases.
Main Methods:
- Data collected from French pediatric wards and 166 microbiology laboratories.
- Included risk factors, symptoms, vaccination status, CSF analysis, treatments, and case fatality rates for bacterial meningitis cases in children (0-18 years).
Main Results:
- 1661 cases of meningococcal meningitis reported between 2001 and 2009 (44.1% of bacterial meningitis).
- Serogroup B (61.3%) was most prevalent, followed by serogroup C (27.0%).
- No serogroup C cases in vaccinated children; 6.5% global case fatality rate, higher for serogroup C (9.2%) than B (5.9%).
Conclusions:
- Meningococcal bacteria cause approximately 50% of meningitis cases in France.
- Effective serogroup B and C vaccines could significantly reduce the burden of meningococcal meningitis.
- This study represents one of the largest series of microbiologically documented meningococcal meningitis cases.
Related Concept Videos
Bacterial Meningitis II: Pathophysiology
Bacterial Meningitis I: Introduction
Viral Meningitis
Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
Arboviral Encephalitis

